#JANX hashtag - Bluesky

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Janux Therapeutics (Nasdaq: JANX) reported Q4 and full-year 2025 results highlighting clinical progress, a strategic collaboration with Bristol Myers Squibb, leadership hiring, and a strong year-end balance sheet. Key metrics include $966.6M cash and investments, Phase 1 activity across JANX007/008/011, and a $50M near-term collaboration payment.Clinical readouts show median rPFS of 7.9–8.9 months for JANX007 and confirmed/unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients. Company expects additional 2026 updates.

1 month ago

#JANX Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

New immune therapy targeting EGFR moves into broader cancer testing Janux completes Phase 1a dose escalation of JANX008 and opens expansion cohorts in multiple EGFR+ solid tumors, with more study updates expected.

3 months ago

#JANX Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Most Searched, Monday December 1, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 1st - #CNCK #DNN #EXK #ALIT #ONDS #HIVE #BBWI #FLYE #ZOMDF #WAST #UAVS #TLRY #RLX #NNDM #JANX #IPNFF #GFAI #CLEZ #RXRX #BGM - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Janux Therapeutics Advances Cancer Pipeline with $996M War Chest, Secures $10M Merck Payment Janux reports strong Q2 with $996M cash position and Merck milestone achievement. Multiple clinical readouts expected H2 2025 for JANX007 and JANX008. Learn more.

7 months ago

#JANX Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Janux Therapeutics Reveals Breakthrough Cancer-Fighting Platform with First-in-Class Autoimmune Treatment Potential Novel TRACTr and ARM platforms show promise in cancer and autoimmune diseases. See breakthrough data on PSMA-TRACIr combo and CD19-ARM development. Learn more.

8 months ago

#JANX Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Janux Therapeutics (NASDAQ: JANX) has reported its Q1 2025 financial results and provided key business updates. The company has initiated Phase 1b expansion studies for JANX007 in taxane-naïve mCRPC patients, with updated results showing a median radiographic progression-free survival (rPFS) of 7.5 months across 16 patients. For patients treated at higher doses (6mg and 9mg), the median rPFS reached 7.9 months. The company plans to initiate three additional Phase 1b expansion studies for JANX007 in different mCRPC patient populations. Financially, Janux maintains a strong position with $1.01 billion in cash and investments as of March 31, 2025. The company reported R&D expenses of $25.1 million and a net loss of $23.5 million for Q1 2025. Updates on both JANX007 and JANX008 clinical programs are expected in H2 2025, and the company plans to host an R&D Day in mid-2025 to showcase its preclinical pipeline.

10 months ago

#JANX Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

11 months ago

BREAKING NEWS: ( NASDAQ: #JANX ) JANX - Historical Price Movements Surrounding Earnings

0 0 0 0

11 months ago

News; ( NASDAQ: #JANX ) Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

0 0 0 0

Promising 7.5 Month PFS: JANX007 Expands to Earlier-Stage Prostate Cancer Treatment in Phase 1b Trial New Phase 1b expansion studies target earlier-stage prostate cancer patients. Updated data shows 7.5-month progression-free survival. See full efficacy results.

11 months ago

#JANX Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend with average directional index, Wed Apr 23rd - #AREN #OKYO #GAUZ #VBTX #SIGA #RLMD #PESI #NEON #SNOA #JANX #IRIX #FHTX #EDIT #DRCT #CNCK #AMLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Apr 17th - #UPB #SHFS #AOBI #AGEN #CMRX #DXPE #IMG #JANX #KOD #TATT #PFBC #NEXN #WBX #SBH #RMT #ORN #LEO #FBMS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Janux's Prostate Cancer Drug Shows Perfect Response Rate: What Makes This Clinical Data Special? Janux reports impressive 100% PSA50 response and 50% objective response rates in prostate cancer trial, while maintaining $1.03B cash following recent $402.5M raise.

1 year ago

#JANX Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Janux Therapeutics Appoints Former Amgen Director as Chief Medical Officer Janux strengthens leadership with Dr. Zachariah McIver, bringing 20+ years of immunotherapy expertise as company advances Phase 1 cancer treatment trials.

1 year ago

#JANX Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Janux Therapeutics Launches Massive $350M Public Offering to Fuel Clinical Pipeline Growth | JANX Stock News Janux Therapeutics prices $350M offering at $63/share, including common stock and pre-funded warrants. Proceeds to advance clinical development pipeline and corporate initiatives.

1 year ago

#JANX Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#offering #investing #StockMarket

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Janux Therapeutics Launches Massive $300M Public Offering to Fuel Clinical Pipeline Growth | JANX Stock News Biotech firm Janux Therapeutics announces substantial $300M stock offering with top-tier underwriters to accelerate clinical development programs and expand operations.

1 year ago

#JANX Janux Therapeutics Announces Proposed Public Offering

#offering #investing #news

www.stocktitan.net/news/JANX/janux-therapeu...

0 0 0 0

Trade Desk HQ

@lambokitten.bsky.social

1 year ago

x.com/WolfOnTheRis...

#JANX

1 0 0 0

1 year ago

NEWS: ( NASDAQ: #JANX ) JANX Price Target Alert: $100.00. Issued by BTIG

#StockMarket #News

1 0 0 0